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COVID-19 is the respiratory illness caused by the novel coronavirus, SARS-CoV-2. Cytokine storm appears to be a factor in COVID-19 mortality. 
Echinacea species have been used historically for immune modulation. A previous rapid review suggested that Echinacea supplementation may 
decrease the levels of pro-inflammatory cytokines involved in cytokine storm. The objective of the present systematic review was to identify all 
research that has assessed changes in levels of cytokines relevant to cytokine storm in response to administration of Echinacea 
supplementation. The following databases were searched: Medline (Ovid), AMED (Ovid), CINAHL (EBSCO), EMBASE (Ovid). Title and abstract 
screening, full text screening, and data extraction were completed in duplicate using a piloted extraction template. Risk of bias assessment was 
completed. Qualitative analysis was used to assess for trends in cytokine level changes. The search identified 279 unique publications. After full 
text screening, 105 studies met criteria for inclusion including 13 human studies, 24 animal studies, and 71 in vitro or ex vivo studies. The data 
suggest that Echinacea supplementation may be associated with a decrease in the pro-inflammatory cytokines IL-6, IL-8, and TNF, as well as an 
increase in the anti-inflammatory cytokine IL-10. The risk of bias in the included studies was generally high. While there is currently no 
substantive research on the therapeutic effects of Echinacea in the management of either cytokine storm or COVID-19, the present evidence 
related to the herb’s impact on cytokine levels suggests that further research may be warranted in the form of a clinical trial involving patients 
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Abbreviations: ARDS, acute respiratory distress syndrome; CCL, C-C motif ligand chemokine; COVID-19, coronavirus disease 2019; CSF, Colony-
stimulating factor;  GM-CSF, granulocyte- macrophage colony- stimulating factor; IFN, interferon; IL, interleukin; MCP, monocyte 
chemoattractant protein; MIP, macrophage inflammatory protein; SARS. Severe acute respiratory syndrome; SARS-CoV-2, severe acute 
respiratory syndrome coronavirus 2; TFN, tumor necrosis factor. 
Introduction 
 
In early January of 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the agent responsible for coronavirus 
disease 2019 (COVID-19)(1). As of June 2021, the global spread of this virus has led to a pandemic with approximately 176 million confirmed 
cases, including over 3.8 million deaths worldwide(2). While the majority of COVID-19 patients experience mild to moderate flu-like symptoms 
(including fever, myalgia or fatigue, and dry cough), severe cases may lead to the development of complications such as acute respiratory 
distress syndrome (ARDS) and multiple-organ failure(3). Current scientific literature suggests that “cytokine storm”’ is the main cause of ARDS 
and multiple organ failure in COVID-19 patients(4) through a pathologic process involving excessive inflammation and interference with 
coagulation leading to clot formation, organ tissue damage (notably in the lungs), multiple organ dysfunction syndrome, septic shock and 
ultimately death(1, 5).  
 
Cytokine storm, also known as cytokine release syndrome, is a phenomenon observed in response to a number of viral infections and is 
characterized by a rapid release of pro-inflammatory cytokines(6). A recent literature review proposed a unified characterization of cytokine 
storm based on three criteria: “elevated cytokine levels, acute systemic inflammatory symptoms and secondary organ dysfunction beyond that 
which could be attributed to a normal response to a pathogen, if a pathogen is present''(7). Cytokines involved in cytokine storm include 
proinflammatory interleukin (IL)-6, IL-8, IL-1β, IL-12 and tumor necrosis factor (TNF), while other cytokines such as IL-10 inhibit the process 
through an anti-inflammatory effect(6). When considering the role of cytokines in COVID-19 specifically, it has been observed that higher levels 
of IL-6, IL-8 and TNF, at the time of admission, were associated with significantly lower rates of survival after adjusting for demographics and 
comorbidities as confounding variables.(8) An association between higher IL-6 and IL-8 levels and increasing disease severity was also 
observed(8). In another cohort of COVID-19 patients, highly impaired Interferon (IFN) type 1 response was consistent among severe and critically 
ill patients.(9) Decreased levels of INF-α and IFN-β were associated with ongoing elevation in blood viral load and an over-active response of pro-
inflammatory modulators TNF and IL-6(9).  
 
Given the central role of cytokine storm in the progression of severe COVID-19 cases, suppressing this immune response may be an opportunity 
to intervene. As such, several immunomodulatory treatments (including corticosteroids, Janus kinase (JAK) inhibitors, hydroxychloroquine, 
Tocilizumab and Colchicine) as well as antivirals like remdesivir and lopinavir/ritonavir have been proposed, but results have been mixed (10-14). 







combination with remdesivir reduces recovery time(15-17). Despite advances in treatment approach, severe COVID-19 remains challenging to 
treat and additional effective interventions are needed(10-14).   
 
Herbal medicines, including species of Echinacea, have been used historically to modulate the immune system. The genus Echinacea has nine 
different species, with Echinacea angustifolia, Echinacea pallida and Echinacea purpurea commonly employed for medicinal purposes, notably as 
a treatment for various upper respiratory tract infections and inflammatory ailments(18). Although the active constituents of the Echinacea 
genus are well known (e.g., polysaccharides, glycoproteins, caffeic acid derivative and alkamides), their exact mechanism of action is not well 
understood(19-21). Nonetheless, this herbal therapy seems to be well tolerated with few adverse reactions reported(20).  
 
Previous research indicates that the use of Echinacea may decrease the duration and severity of respiratory tract infections(18), making it a 
potential candidate to mitigate the symptoms of COVID-19. However, given its ability to stimulate the immune system, there are concerns that 
using this herb to treat COVID-19 could contribute to or exacerbate the potential for cytokine storm. Interestingly, a recent rapid literature 
review of clinical trials suggests that Echinacea may have the opposite effect, decreasing pro-inflammatory cytokines and increasing anti-
inflammatory cytokines, which may provide a therapeutic benefit in the management of COVID-19(22). As such, the objective of the present 
systematic review is to identify all research that has assessed changes in levels of cytokines relevant to cytokine storm in response to 
administration of Echinacea supplementation.  
 
Methods  
Search Strategy and Databases 
The following search terms were used: (Echinacea OR Echinacea angustifolia OR Echinacea purpurea OR coneflower) AND (Cytokine* OR 
cytokine storm OR cytokine release syndrome OR chemokine* OR interferon* OR interleukin* OR tumour necrosis factor* OR colony-stimulating 
factor*). The databases searched included Medline (Ovid), AMED (Ovid), CINAHL (EBSCO), EMBASE (Ovid). The search strategy was informed by 
an earlier rapid review(22) and conducted on July 14, 2020. An update of the search was conducted on April 12, 2021.  
Study Selection 
Inclusion criteria: 1) administered Echinacea, 2) reported changes in levels of cytokine relevant to cytokine storm (at least one of the following: 
interferon, interleukin, chemokine, tumor necrosis factor, colony-stimulating factor) and 3) experimental or observational study design, 
including humans or animals, in vitro/ex vivo studies, and case reports. Exclusion criteria: 1) administration of echinacea in combination with 
other herbal, medical or nutritional supplements, 2) Reviews, systematic reviews, commentaries, and historical articles. Abstract and full text 
screening was completed independently in duplicate with any disagreement resolved by consensus.  








Data extraction was completed using piloted extraction templates for human, animal, and cell culture studies. Complete study data was 
extracted by one reviewer. A second reviewer independently extracted outcome data and completed risk of bias assessment in duplicate; any 
disagreement was resolved by consensus. Predefined outcomes of interest included: changes in chemokines, interferon, interleukin, tumor 
necrosis factors, and colony stimulating factors, as well as the incidence of cytokine storm. The change in cytokine level reported in each study 
was extracted (i.e., increase, decrease or no change in cytokine production). The predefined study characteristics that were extracted from the 
human studies included: author, sponsorship, study design, study population, Echinacea species, Echinacea dose and duration, control or 
placebo, number of participants, inclusion/exclusion criteria, change in cytokine levels and incidence of cytokine storm. The characteristics 
extracted from the animal studies included: author, sponsorship, animal model, infection or method immune stimulation, Echinacea species, 
Echinacea dose, from and standardization, control or placebo, number of subjects, change in cytokine levels, and incidence of cytokine storm. 
The characteristics extracted from the cell culture studies included: author, sponsorship, cell or tissue culture, infection or method immune 
stimulation, Echinacea species, Echinacea dose, form and standardization, duration, control or placebo, change in cytokine levels, and incidence 
of cytokine storm. 
Risk of Bias Assessment  
Risk of bias assessment was completed using the following tools: Cochrane Risk of Bias 2.0 (randomized clinical trials)(23), ROBINS-I (non-
randomized trials)(24), NIH Quality Assessment Tool (pre-post studies with no control group)(25), OHAT (animal studies)(26), and ToxRtool (in 
vitro studies)(27).  
Data Analysis  
Studies were grouped based on methodology. The number of studies reporting increases, decreases or no change in each cytokine were counted 
and presented in figures to assess for trends visually. Statistical pooling was not feasible due to a qualitative assessment of heterogeneity made 
by the author team. 
Results 
Of the 436 records identified, 105 studies met criteria for inclusion in the present systematic review (Figure 1). Excluded studies are listed in 
Supplemental File 1. Of the 13 studies involving human participants, seven were randomized clinical trials(28-34), three were non-randomized 
trials(35-37) and three were pre/post uncontrolled trials(38-40). Twenty-four studies reported outcomes related to animal experiments(41-63) 
and 69 studies reported outcomes related to in vitro or ex vivo studies(39, 64-131). Tables 1, 2 and 3 present the characteristics and results of 
the human, animal and in vitro/ex vivo studies respectfully.  
 
The most commonly studied Echinacea species in human, animal and in vitro/ex vivo studies alike was E. purpurea. Approximately 66% of all 
studies used E. purpurea alone and another 19% used E. purpurea in combination with other species. The second most commonly studied 








Human studies were conducted primarily in the USA (38%, n=5), followed by Italy and Germany (23%, n=3 each), Indonesia (8%, n=1) and 
Ukraine (8%, n=1). Of the 13 human studies, eight (61%) examined the effects of Echinacea on healthy adults. The remaining five studies 
examined the effects of Echinacea on: healthy male triathletes training for competition(34), healthy adults exposed to rhinovirus(30), teenagers 
and adults with new inset of the common cold(28), adults in clinical remission of chronic herpes(35), and COPD outpatients(29). The largest 
human study was a clinical trial with 713 participants(28) and the smallest were two non-randomized studies without a control group(39, 40) 
with six participants each. The average number of participants in human studies was 112 (SD=208) and the median was 40. The Echinacea 
dosage and duration of treatment employed also varied widely, ranging from a one-time injection containing 5mg of Echinacea polysaccharides 
(36) to a daily dose of 8000mg of Echinacea capsules for 28 consecutive days(32). A total of four studies(31, 32, 34, 37) implemented 28-day 
interventions and three employed a one-time dose(36, 38, 40). Concerningly, two studies(33, 35) did not specify the dosage of Echinacea used. 
Moreover, Echinacea tablets or soft gel capsules were the most common type of intervention. Additional interventions included Echinacea 
lozenges, syrup, juice and tinctures. All of the human studies except for one(31) assessed changes in interleukins, with IL-6 being the most 
common, closely followed by IL-8, IL-1B, then IL-10, IL-2, IL-12 and IL-3. The second most commonly studied cytokine was TNF (61%, n=8). Lastly, 
three studies (23%) assessed changes in INF and only one (8%) assessed changes in GM-CSF. None of the human studies included assessed 
changes in chemokines. 
Animal studies were conducted in mouse or rat models, although studies also included dogs(54), tilapia(45), and guinea pigs(55). Sixteen trials 
had a duration of at least two weeks while five lasted four to seven days(41, 43, 50, 57, 131) and three lasted one day or less(60, 61, 63). The 
daily dose of Echinacea varied widely from 5 to 500mg/kg per day.  
The cell culture studies used a variety of immune cells. Immune stimulation was achieved through a variety of methods; the most common 
where exposure to LPS (n=29), viruses (n=14) and phytohemagglutinin and/or phorbol 12-myristate 13- acetate (n=10). Studies assessed changes 
in the amount of cytokines produced or changes in genetic expression following exposure to Echinacea.  
 
Table 1:  Characteristics of the human studies included.  




































Health (NIH).  
Placebo 
controlled 
RCT (4 arms) 
People 12-80 





















per day (5.1 
g per day) for 
4 days. 
 
1 tablet = 
675 mg of E. 
purpurea 



















































and a score 
























rise in mean 
nasal rinse 







































of age (mean 




of the aerial 




twice a day 
for 7 days 
and either 
tablets with  
1) 500 mg E. 
purpurea or  
2) 500 mg of 
E. purpurea 
with 10 mg 


























40+ years of 



















































































































































Dose: 1.5 ml 
of tincture 
containing 
300 mg of 
echinacea 
extract three 










































CO2, 2) 60% 












































test virus at 
screening or 
at day zero. 
significant 


























































whole herb  
Two capsules 
twice per 
day for a 
daily total of 
either: 





2) 780 mg of 
E. purpurea 
(4% phenols) 







































































464 mg of E. 
purpurea, 
and 36 mg of 
E. 
angustifolia 
(EPA); 4) 908 




464 mg of E. 
purpurea, 46 
mg of E. 
angustifolia 
and 1500 mg 
of larch 
arabinogalac

























































matched trial  









day for a 
total daily 

















y active (i.e., 


























































28 ± 5.8 
































(C. Bode and 




with a body 
mass index 





mono       
two times 










































































27.5 ± 5.3 
years of age, 
with VO2 
max > 52ml/ 















































2R and IL-6 































































































alcohol use.   
competition









to baseline.  






























































of 60% E. 
purpurea 













































































































































































































































































































10 mL of 





100 mg of 
Polinacea 
(4.7 mg of 
echinacoside 


























































































































































mg, 0.21 mg 





















2 hours post 
treatment. 
No medicine 
to be taken 
from one 
week before 


























dose did not 
(p=0.059).  
24 h after 
intervention 
the level of 
TNF-α was 
approximatel




for IL-6, 64% 
for IL-8, 73% 











































































































































































1 tablet = 
252 mg of E. 
purpurea 
(aerial parts), 
16 mg of E. 
purpurea 
(root), 12 mg 
of E. 
angustifolia 
(root) and 33 





















































































levels by day 
12. 
 
COPD: Chronic Obstructive Pulmonary Disease; EP; Echinacea purpurea; g: Grams; IFN: Interferon; IL: Interleukin; kg: Kilograms; mg: Milligrams; ml: Millilitres; 
NaCl: Sodium Chloride; NSAID: Nonsteroidal Anti-Inflammatory Drugs; RCT: Randomized controlled trial; TNF: Tumour Necrosis Factor; ug: Microgram  
 
Table 2: Characteristics of the animal studies included.  
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preparations: echinacea fresh 
pressed juice and echinacea 
dried juice 







IL-1, IL-6, IL-10 and 












3.0, 1.2, 0.2, and 0.05 µg/ml 
Dried juice doses: 10, 1.0, 0.I, 
0.03, and 0.01 µg/ml 
 











the Office of 
the Vice 
President for 



















E. purpurea root extract  
 
Doses: 0, 0.1, 1, and 10 mg/mL 
 










No change in 













E. purpurea Standardized commercial 
extract: Echinaforce, A. 
Vogel/Bioforce 
 
Dose used not specified 
 







































EtOH extract was prepared from 
E. purpurea roots. Dodeca-
2E,4E,8Z,10Z-tetraenoic acid 
isobutyl- amide was obtained 
from Chromadex; Santa Ana, CA, 
USA. 
 
Two E. purpurea doses 
containing 4 or 0.9 μg/ml of 
dodeca-2E,4E,8Z,10Z-tetraenoic 
acid isobutyl- amide 
Two dodeca-2E,4E,8Z,10Z-
tetraenoic acid isobutyl- amide 
doses: 1.8 or 0.19 μg/ml  
 








































17 extracts: E. purpurea roots 
were harvested from 17 
cultivation sites across North 
Carolina, pulverized into a fine 
powder, macerated for seven 
days in 75% EtOH at a ratio of 1:5 
(g plant material: mL solvent), 
pressed, and filtered. 
 
Dose of extract #7 used in 
general cytokine and chemokine 
experiments: a dilution of 85% 
EtOH (precipitated) extract was 












































Dose of extracts used in TNF-α 
experiments: 6.7 μL of 75% EtOH 
extracts and 5.8 μL of 85% EtOH 
(precipitated) extracts 
 
Doses of alkylamides: 0,  6.25, 
12.5, 25, and 50 μg/mL 
 
DURATION: 24 hours 
















Three extracts obtained from A. 
Vogel Bioforce AG, Switzerland: 
herba, root, and combo herba + 
root in a ratio of 95:5 
 
Doses: herba extract (9.5 μg/ml), 
radix extract (0.5 μg/ml), and 
comb herba + radix extract (10 
μg/ml) 
 

















LPS (1 µg/ml) E. purpurea 
 
Extract: Butanol partitioned 

































111- 004)  
 
Dose: 100 μg/ml 
 
DURATION: 0.5, 4 or 12 hours 
 
IL-5, IL-IR2, CXCR4, 




IL-1β, IL-4, IL-13, 
IL, TNF-α, 
CCR2,CCR3,CCR4, 
CCL2, CCL4, CCL8, 











Seeds from E.purpurea were 
treated with absolute EtOH and a 
1:10 dilution of deomestos 
 
Dose not stated.  
 





























50 ng/mL LPS 
E. purpurea 
 
15 mg/mL standardized extract 
 
DURATION: 48 hours 
  
Ech was the 
positive 
control. 
Exposure to a 
cytotoxic 
compound 

































Crude water extract of E. 
purpurea. Cynarin was extract 




Dose for both: 100 μg/mL 
 




















Program for the 
financial 













Advantagoues roots of E.pallida 
(11.4 g) and E.purpurea (8.6g) 
were cut into approx 1cm length  
 
























extract called Polinacea that was 
prepared by the authors using a 
patent 
 
Extracts doses used: 0, 20, and 
60 μg/mL 
 
















Cancer Centre  







Extract doses used: 0,10,25, 100 
and 250 μg/mL 
 
































Extract: fresh aerial parts were 
extracted with water, ethanolic 
precipitation, and size-exclusion 
chromatography 
 
Extract doses used: 0, 10, 25, 100 
and 250μg/mL 
 









































E. purpurea Extract obtained from Shandong 
Qilu Animal Health Co., Ltd. 
Chemical composition of extract: 
cichoric acid (3.045%), caftaric 





Dose: 100 µg/ml 
 






(10 ng/mL) + 
LPS (10 
ng/mL) or IL-
4 (20 ng/mL) 
Increased 
secretion: IFN-γ, 
IL-1α, IL-6 and 
















LPS (3 µg/ml) E. purpurea 
 
Standardized extract of 
echinacea (4% total phenolics) 
obtained from Stryka Botanics 
Co., Inc., Hillsborough, NJ. 
 





(3 µg/ml) for 
macrophages 
and IL-12 (3 




































E. purpurea dried extract, 
polyphenols content min 4%, 
dissolved in EtOH and water. 
 
Dose not specified 
 








production: IFN-γ  
 







































acid isobutylamide was 
synthesized and used in doses of 
25, 50 and 100 μM 
 
































































A series of isolations from a 
methanolic extraction of E. 
purpurea were carried out to 
yield (1) a fraction containing an 
alkamides mixture, (2) dodeca-
2E,4E,8Z,10Z(E)-tetraenoic acid 
isobutylamide, and (3) cichoric 
acid. 
 















IL- 1β, IL-6, IL-10, 
IL-12p70, IL-13, IL-













tetraenoic acid isobutylamide 
dose: 5 and 100 µM 
Cichoric acid dose: 50 and 100 
µM 
 











2003’’, at the 
38th annual 



















N/A E. purpurea 
 
Liquid extract: fresh Echinacea 
root juice, mature seed, fresh 
leaf juice and fresh fruit juice 
extracted in 44–50% alcohol 
 
Solid extract: solid extract (dried 
Echinacea root and leaf) 
dissolved in either in distilled 
water or absolute alcohol in the 
ratio of 25 mg of solid extract per 
ml of solvent 
 
Dose of Echinacea preparation: 
1mg/ml 
 
DURATION: 48 hours  
None Increased 
production:  
IL-6, IL-10, MIP-1α 
and TNF-α 
 
No change in 
production: IFN-γ, 












N/A E. purpurea 
tincture  
E. purpurea tincture in a series of 
10-fold dilutions. the active 























DURATION: 48 hours 
IL-1, IL-8, IL-1β, IL-
10 




















Dose: 12.5, 25, or 50 μM 
 


































Extract purchased from 
Shandong Qilu Animal Health 
Co., Ltd. 
Chemical composition of extract: 
cichoric acid (3.045%), caftaric 
acid (1.575%), chlorogenic 





















DURATION: 24 hours 
Luettig, 
1989 (89) 














T Cells - ConA 
at 1 and 5 
μg/ml 
B cells - LPS 
50 μg/ml  
Macrophages 
in virto - LPS 
100 μg/ml 
Arabinogala
ctan from E. 
purpurea  
 
Varied per experiment, but 
ranged from 3.7-500 μg/mL 
 











β2, IL-1 and TNF-α 
 






























Alkylamides concentration 0.2 
ng/mL; cichoric acid 
concentration 0.8ng/mL  
 


































































Root tinctures of each species 
extracted in 50% EtOH/50% 
water at a ratio of 1 part plant/9 
part solvent. Tinctures were 

























ages of 19 
and 36 who 
donated 
blood 8 hours 












Dose: 1:12.5 dilution 
 














No change in 
levels: IFN-γ, IL-12 















Radiation E. purpurea 
 
360mg/kg; mice administered 
treatment every other day every 
other day 
 







































Fatty acid amide was chemically 
synthesized de novo, and analogs 
were created by altering the 
double bonds and/or the alkyl 











































Dose: 100 µM 
 
















LPS (1 µg/ml) E. 
angustifolia 
The roots were exhaustively 
treated with 90% EtOH for 
echinacoside extraction and then 
counter- extracted with n-hexane 
for isobutylamides elimination. 
Wet roots were extracted with 
15% aq.  
 

























root extract  
Extract is prepared by 
supercritical CO2-extraction of E. 
purpurea roots. 
 
Dose: 20 µg/ml 
 






















; Dr. August 


























Commercial ethanolic root 
extract standardized to ≥4% 
echinacoside 
 
Dose: 10 µg/ml 
 







































0.1, 0.4 and 1.0 μg/ml 
 





















































A2 was isolated from E. 
purpurea. A1 and A3 were gifted 
by MediHerb, Australia. 
 
Dose: 5 nM, 50 nM, 500 nM, and 
5000nM 
 














IL-1β, IL-6, IL-8, IL-






















10 μg/mL, 50 μg/mL, 250 μg/mL 
 






IL-1α, IL1β, IL-8, IL-
























5 μg/mL, 20 μg/mL, 80 μg/mL, 
320 μg/mL 
 







IL-1α, IL-1β, IL-6, 






















E. purpurea Echinaforce - patient took 4 1mL 
doses for 5 days, then 10 1mL 
doses for 3 days. Blood sample 
taken each day for analysis;  
Echinaforce phytochemical 
profile: 264.4μg/ml caftaric acid, 
40.2μg/ml chlorogenic acid, 
313.8 μg/l cichoric acid, 6.9 
μg/ml echinacoside, 35.9 μg/ml 
dodeca tetraene; Echinaforce 
made from freshly harvested 
herbs and roots of E. purpurea in 
a 95:5 ratio.  
 
DURATION: 8 days of 
supplementation, blood cells 































E.purpurea extract; 0.1 μg/mL, 1 
μg/mL, 10 μg/mL, 50 μg/mL and 
100 μg/mL in 95:5, 75:25, 50:50, 















United States  
ng/mL PMA; 


























Echinacea consitituents; stock 
concentration of 5mg/mL diluted 
to final concentration of 0.625-
25 μg/mL 
 





























3 extracts for each Echinacea 
species: 50% EtOH, cold water 
infusion, and hot water infusion 
[1 part plant to 9 parts solvent]. 
Extracts were stored at 4°C and 


























Dose not stated. 
 
DURATION: 24 hours 
Decreased 
production: IL-10 


































Method of extraction not stated. 
Extracts were stored at -20°C for 
1 month before beginning 
experiments.  
 
Dose not stated. 
 






IL-1β and TNF-α 
 
No change in 
















































50% ethanolic tinctures of roots 
from each species [1 part plant, 9 
parts solvent]. 
 
Dose: 1:12.5 dilution 
 






































cells (from 16 
subjects 
between the 
ages of 19 






Separate 50% EtOH tinctures 
prepared from roots, stems, 
leaves, and flower. 
Tincture aliquots were stored at 
three different temperatures (4, -
20, and -80°C) for 21 hours 
before testing. The -20°C aliquots 
were saved and tested again 1 
month later. 
 
Dose: 1:12.5 dilution 
 






IL-1β, IL-10 and 
TNF-α 
 




















and (2) 90 
min of cycling 






Separate 50% EtOH tinctures 
prepared from roots and flowers. 
Extracts were stored at−80°C 
undisturbed for 3 years before 
the study took place. 
 
Dose: 50 μL 
 













No change: IL-1β, 








from NIEHS and 









3 separate tinctures of dried root 
samples of the three species 
made with 50% EtOH/50% water 
at a ratio of 1:9 parts plant 
Negative 
control: EtOH 



















material:solvent. E. purpurea 
roots were also made into a 4th 
extract with 95% EtOH and using 
the Soxhlet apparatus. 
 
Dose: 1:12.5 dilution 
 





No Change in 





funds given to 






















Root tinctures of each species 
extracted in 50% EtOH/50% cell 
culture water at a ratio of 1:9 
parts plant material:solvent.  
 
Dose: 50 μL/well 
 








Increased levels:  
IL-10 and TNF-α  
 
No change in 















E. purpurea Two extracts: 
E1: an expressed juice extract of 
the aerial parts of E. purpurea 
E2: a 50% alcoholic tincture, 
derived from E. purpurea roots 
(1:9 w/v) 
 
Dose: 100 μg/mL of E1 or 


























DURATION: 24 to 96 hours 
virally 
infected cells 
IL-3, IL-5, IL-6, IL-7, 








Not stated The tracheo-
bronchial line 
BEAS-2B, H-1 










types 1A and 
14 
E. purpurea Echinaforce by A. Vogel Bioforce 
AG, Switzerland: a 65% ethanol 
extract of freshly harvested 
aerial parts supplemented with 
5% roots. 
 
Dose: dilutions of 1:20, 1:100, 
1:200, and 1:400 
 


































types 3 and 
11, and HSV 
E. purpurea Echinaforce obtained from A. 
Vogel Bioforce AG, 
Roggwil,Switzerland, batch no.: 
018451: standardized 
preparation derived by EtOH 
extraction of freshly harvested E. 
purpurea herb and roots(95:5) 
 
Dose: 1:100 dilution of Echinacea 
in DMEM without serum, 












IL1-α, IL-1β, IL-5, 
IL-6, IL-8, MIP-1α, 
MIP-1β, GRO-α, 
MCP-1, CCL5 and 











concentration of 160µg/mL (dry 
mass/vol) 
 


















E. purpurea Echinaforce by A. Vogel Bioforce 
AG, Switzerland: a 65% EtOH 
extract of freshly harvested 
aerial parts supplemented with 
5% roots. 
 
Dose: 1:100 dilution of 
Echinaforce 
 





































E. purpurea Echinaforce by A. Vogel Bioforce 
AG, Switzerland: a 65% EtOH 
extract of freshly harvested 
aerial parts supplemented with 
5% roots. 
 
Dose: 1:100 dilution of Echinacea 
in DMEM without serum, 
corresponding to a final 














secretion: IL-4, IL-6 
and IL-8, MIP-1α, 





























E. purpurea Echinaforce by A. Vogel Bioforce 
AG, Switzerland: a 65% EtOH 
extract of freshly harvested 
aerial parts (drug extract ratio 
1:12) supplemented with 5% 
roots (drug extract ratio 1:11). 
 
Dose: 1:100 dilution of Echinacea 
in DMEM without serum, 
corresponding to a final 
concentration of 160µg/mL (dry 
mass/vol) 
 











secretion: IL-6, IL-8 

































0.033 μg/mL, 0.1 μg/mL, 0.33 
μg/mL, 1 μg/mL, 3.3 μg/mL  
 




























100 μg of LPS 
or μg of EPS 
Purified 
polysacchari
des from E. 
purpurea 
Polysaccharides were purified by 
chromatography from alkaline-
water extracts of E. purpurea. 
 
Dose: 100 µg 
 





























LPS E. purpurea; 
IL-6 2400, 
1200, 600, 




IL-6 48 hours // IL-12, IL-1B 24 
hours. 
 













and IL-12, TNF-α 
 




















TNF 50 μg /mL, 100mg/mL // 
Chemokines - varying degrees of 
alkylamides for fractions 1-13 
and CL (precise concentrations 
Medium  Decreased 
production: CCL3, 

















EE, HL, ML, 







Figure 1)  
and chemical structures in paper, 
Table 1 and Fig. 3)  
 





Not stated  BEAS-2B Rhinovirus 
type 14 (RV 
14) (infection 












(D.C.) and E. 
pallida 
(Nutt.) Nutt.  
250 μg/mL 
 
DURATION: 48 hours 
 




















CFU assay - 1:200 (50 μg/mL), 
1:400 (40 μg/mL), 1:800 (20 
μg/mL) // Cytokine assay - 1:100, 
1:200, 1:400 // NFκB p65 


































Human DCs  LPS (1 µg/ml) E. purpurea 






Used 100 μg/mL for data 
presented  
 


































Concentration of cichoric acid   
8.4% w/w and rutin 22.3% w/w  
 






IL-1β, IL-8, IL-18, 



















E. purpurea Dried and ground fresh herb 
homogenized in RPMI and 
filtered. 
 
































) or tablet  
E. purpurea tincture containing 
0.018mg/mL of dodeca-
2E,4E,8Z,10E/Z-tetraenoic acid 
isobutylamides and 1 E.purpurea 
tablet is 0.006mg 
 





IL-8 and  
TNF-α  
 






was donated by 
Indena s.p.a.;  
MiUR (PRIN 05) 
and Università 
degli Studi della 























Hydroethanolic root extract 
called Polinacea donated by 
Indena s.p.a. (Settala, Milan, 
Italy). 
 
Doses: 0, 6.3, 20, 60, and 180 
µg/ml 
 











































































EPP (2−2, 2−3, 2−4 mg/mL, 
marked as EPPH, EPPM, EPPL, 
respectively) or sEPP (2−7, 2−8, 
2−9 mg/mL, marked as sEPPH, 
sEPPM, sEPPL, respectively) 
 





















and the Office 
of Dietary 
Supplements, 
Splenocytes  ConA of 1 
and 3 μg/ml 






130mg/kg delivered orally  
 






secretion: TNF-α  
 
No change in 
secretion: IL-1β 

































LPS (1 µg/ml) E. 
angustifolia, 









23 and 24 
E. paradoxa var. paradoxa was 
fractionated into 5 fractions by 
semipreparative HPLC system. 
Doses: 184 μg/ml (fraction 1), 75 
μg/ml (fraction 2), 101 and 20 
μg/ml (fraction 3), 20 and 3.2 
μg/ml (fraction 4), 36 and 20 
μg/ml (fraction 5), 187 and 20 
μg/ml (fraction 6). 
 
Bauer ketones 22, 23 and 24 
(present in fraction 5) where 
chemically synthesized. 
Doses: 3.1 μM (#22), 1.6 μM 
(#23), and 9.7 μM (#24). 
 











IL-6 and TNF-α   
1 
*1 = reliable without restrictions, 3= unreliable  
BEAS-2B: Human Bronchial Epithelial Cell Line; ConA: Concanavalin A; CXCL/CCL: Chemokine Ligand; CL: Chloroform Layer; DC: Dendritic Cells; 
DMEM: Dulbecco’s Modified Eagle Medium; DMSO: Dimethylsulfoxide; EE: Ethanol Extract; EPP: E. purpurea Polysaccharide; EPS: Extracellular 
Polymeric Substances; EtOH: Ethanol; g: Gram; GM-CSF: Granulocyte-macrophage Colony-stimulating Factor; GRO: Growth Regulated Oncogene; 
HaCaT cells: Human Keratinocyte Cells; HL: Hexane Layer; HMC-1: Human Mast Cells; H2O2: Hydrogen Peroxide; IFN: Interferon; Il: Interleukin; 
kg: Kilogram; LPS: Lipopolysaccharide; MCP: Monocyte Chemoattractant Protein; MIP: Macrophage Inflammatory Protein; ml: Millilitre; ML: 
Methane Layer; MNL: Mononuclear Leukocyte; MRSA: Methicillin- resistant Staphylococcus Aureus; MSSA: Methicillin-susceptible 
Staphylococcus Aureus; NADPH: Nicotinamide adenine dinucleotide phosphate; NFκB: Nuclear Factor kappa B; ng: Nanogram; NK: Natural Killer; 








Phorbol-12-myristate 13-acetate plus calcium ionophore; PPAR-γ: Peroxisome Proliferator-activated Receptor gamma; RANTES: Regulated on 
Activation Normal T Expressed and Secreted; RBL: Rat Basophilic Leukemia cells; RPMI: Roswell Park Memorial Institute Medium; SEB: 
Staphylococcal enterotoxin B; sEPP: Sulfated E. purpurea Polysaccharide; TNF: Tumour Necrosis Factor; TPH-1: Tryptophan hydroxylase-1; μg: 








Change in cytokine levels  
The changes in cytokine levels that followed Echinacea supplementation are presented in Figure 2. Results are presented for the cytokines 
relevant to the progression of cytokine storm. Among the human studies, decreased levels of the pro-inflammatory cytokine IL-6, IL-8, and TNF 
were reported by 57, 50, and 62% of studies that measured these cytokines, respectively.  Among the animal studies decreased levels of pro-
inflammatory cytokines IL-1, IL-6, and TNF, were reported by 73, 78, 74% of studies that measured these cytokines, respectively.  However, 
increased levels of the pro-inflammatory cytokine IL-2 were reported by 57% of animal studies. In addition, an increase in levels of the anti-
inflammatory cytokine IL-10 were reported by 57% of animal studies that measured this cytokine. Among the cell culture studies, decreased 
levels of pro-inflammatory cytokines IL-6, IL-8, CCL2, CCCL3, and CCL4 were reported by 63, 70, 67, 75, 71% of studies that measured these 
cytokines, respectively. Moreover, nearly two thirds of the cell culture studies that measured levels of the anti-inflammatory cytokine IL-10 
reported an increase. IFN levels were increased in the majority of human, animal, and cell culture studies; while this cytokine is considered to be 







Risk of Bias Assessment 
The results of the risk of bias assessments for the human RCT and non-RCT studies are presented in Figures 3 and 4. In total, six of these studies 
had a “high risk of bias”, two studies had “some concerns” or “moderate risk of bias” and two studies had “low risk of bias”. Among the pre-post 
human studies, two received a rating of “fair” and one received a rating of “poor”. Among the animal studies, each one received a rating of 
“probably high risk of bias” in at least one category. Three received a rating of “definitely high risk of bias” in one category. Additional 
information on the risk of bias assessment for the pre-post and animal studies is found in Supplemental File 2. Among the cell culture studies, 
thirty-eight (55%) received as score of 1 corresponding to “reliable without restrictions”. Thirty-one (45 %) received a score of 3 corresponding 















The present systematic review identified all human, animal, and cell culture data reporting the impact of Echinacea supplementation on cytokine 
levels. The data suggest that Echinacea supplementation may be associated with a decrease in the pro-inflammatory cytokines IL-6, IL-8 and TNF 
as well as an increase in the anti-inflammatory cytokine IL-10. In addition, it may be associated with an increase in IFN, a pro-inflammatory 
cytokine reported to be low in patients with COVID-19. Overall, the findings of the human and animal studies were more likely to report 
primarily anti-inflammatory effects. Ex vivo and in vitro studies demonstrated more of a mixture of pro- and anti-inflammatory effects; however, 
given that they were conducted in the isolation of cell culture rather than in the context of a highly complex, functioning immune system, the 
results may be less relevant to use in humans. The findings suggest that the use of Echinacea supplementation may be useful in the prevention 
or management of COVID-19-related cytokine storm in humans, however further targeted studies are needed.  
Levels of IL-6 and TNF both independently predict COVID-19 disease severity and mortality(8) and may be important therapeutic targets. 
Therapies aimed at inhibiting these cytokines have demonstrated improvements in the clinical course of severely ill COVID-19 patients. A meta-
analysis of studies administering the IL-6 receptor monoclonal antibody tocilizumab to patients with severe COVID-19 revealed a reduction in 
mortality and the need for mechanical ventilation(132). The effects of other immunomodulatory agents including anakinra, an inhibitor of IL-1, 
and sarilumab and siltuximab, inhibitors of IL-6, were inconclusive(133). Observational registry data from patients with inflammatory bowel 
disease who contracted COVID-19 suggest a possible benefit from taking anti-TNF medication in terms of a composite outcome of death or 
hospital admission, however not with either outcome alone.(134) A call to prioritize the study of anti-TNF therapy has been made(134). Because 
IL-6 and TNF are independently associated with clinical outcomes, it has been hypothesized that therapy targeted at the inhibition of both 
cytokines simultaneously may yield additional benefit and warrant study(8). Echinacea may decrease production of these two cytokines.  
Among the studies identified in the present review, more studies reported an increase in IFN production than a decrease following Echinacea 
supplementation. While IFN-α and β are considered proinflammatory in nature, they also play a critical role in exerting an antiviral effect. 
Observation of depressed levels of IFN-α and β among COVID-19 patients has occurred(9). While the trial reporting this finding was primarily 
cross-sectional, sequential assessment found that the depressed levels of IFN-α preceded worsening of disease severity and transfer to more 
intensive care(9). The virus SARS-CoV, the causative agent of severe acute respiratory syndrome (SARS), inhibits production of IFNs in order to 
diminish the innate immune response of the host(135).  A need to explore therapeutic approaches to increase IFN in the treatment of COVID-19 









Additional evidence that may be considered regarding the potential usefulness of Echinacea in the management of COVID-19 include the herb’s 
ability to decrease the severity and duration of acute respiratory tract infections(22) and in vitro data demonstrating direct antiviral effect of 
Echinacea against several coronaviruses including SARS-CoV-2(136).  
The present review has several strengths and limitations. Strengths of the review include a rigorous search strategy that was conducted in 
multiple databases, as well as duplicate screening and data extraction. The review process is limited by a high level of heterogeneity among the 
included studies and subsequently, the inability to complete meta-analysis. The findings are limited by the high risk of bias found in many of the 
included studies. They are also limited by the fact that none of the studies assessed the impact of Echinacea on cytokine changes in patients or 
models of COVID-19. Many of the human studies involved healthy participants or participants with relatively mild infections such as the common 
cold. The animal and cell culture studies used a variety of immune stimulating agents such as lipopolysaccharide (LPS), bacterial and viral 
infections. While animal models of cytokine storm exist(137), none were used by the studies included in the present review. These factors may 
decrease the generalizability of the findings to the treatment of COVID-19.  
Similarly, the studies did not assess the changes in cytokine levels in models of cytokine storm. Cytokine storm is a complex syndrome involving 
cascades of interdependent inflammatory mediators which changes over the course of clinical progression. Defining this condition has been 
challenging due to the difficulty of differentiating a dysregulated immune response from a physiologic response to a severe infection(7). 
Cytokines play an important role in the host response to an infection but at the same time, may cause harm to the host when released in excess. 
It has been hypothesized that inhibition of cytokine signaling could impair clearance of SARS-CoV-2, and result in worse outcomes such as 
secondary infections; this has been previously observed in the treatment of influenza(138) and subsequent to the use of IL-6 inhibitors in COVID-
19 patients(133). These findings may suggest that immune modulation may be appropriate for only a subgroup of COVID-19 patients. 
Additionally, cytokine production varies over the course of the response to the pathogen. Ideally, the immune response should be proportionate 
to the severity of the infection and result in a return to homeostasis following clearance of the pathogen(7). The importance of timing may be 
relevant to interpreting the findings of the present review. The included studies measured cytokine levels at a variety of timepoints in the course 
of an infection; the impact of timing may account for some of the heterogeneity in the results presented. It has been hypothesized that the 
cytokine storm seen in COVID-19 occurs in two stages. The first stage is an underactive initial immune response which fails to adequately clear 
the virus. Subsequently, in response to the failed clearance, there is an overactive immune response(139). Changes in the immune response at 
different time points in the course of disease progression suggest that the timing of different immunomodulatory therapies may be highly 
important(139).   
Conclusion 
The findings of the present systematic review suggest that the effect of Echinacea supplementation on cytokines may be predominantly anti-
inflammatory, including the inhibition of cytokines that play a key role in the progression of severe COVID-19. Investigation of the potential 
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Figure 1: PRISMA flow diagram of included studies.  
Figure 2: Change in cytokine levels following Echinacea exposure. A: Human studies, B: animal Studies, C: Cell culture studies 
Figure 3: Risk of Bias 2.0 for human randomized controlled trials.  
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 Modulation of the immune system has been identified as a possible management strategy in 
severe COVID-19.   
 A systematic review of all studies assessing changes in cytokine levels following Echinacea 
supplementation was undertaken.  
 Echinacea supplementation may decrease  the pro-inflammatory cytokines IL-6, IL-8, and TNF.  
 Echinacea supplementation may increase the anti-inflammatory cytokine IL-10. 
 Clinical trials assessing the effectiveness of Echinacea in the treatment of cytokine storm in 
COVID-19 may be warranted.  
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